RIVANNA receives FDA 510(k) clearance for Accuro XV musculoskeletal ultrasound imaging system

CHARLOTTESVILLE, Va., May 7, 2026 /PRNewswire/ -- RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital and medical clinic environments.

The 510(k) clearance comes as RIVANNA accelerates development of AI-enabled capabilities for the Accuro XV platform, including BoneEnhance^®, an image segmentation module for enhanced bone visualization, and CADe/x, the first computer-aided detection algorithm for automated fracture identification derived from volumetric ultrasound imaging. Both capabilities are being trained and validated through an ongoing multi-site clinical study spanning eight academic medical centers nationwide.

"FDA clearance of the Accuro XV marks a major inflection point for RIVANNA," said Will Mauldin, PhD, Co-founder and CEO. "This clearance demonstrates the scalability of our core platform — shared AI architecture, imaging hardware, and regulatory pathway — across distinct clinical applications. With no targeted point-of-care solution in this space, we are positioned to define the standard of care for extremity injury triage."

The Accuro XV features a conformable three-dimensional volumetric ultrasound probe that automates large field-of-view image acquisition following initial patient positioning. The system's motorized linear translation technology acquires B-mode images, a 10 cm scan extent; a compliant polyurethane stand-off medium creates a conformable patient contact surface to improve acoustic coupling with irregular anatomies. The cart-based system includes a touchscreen interface, an integrated battery pack for point-of-care mobility, and DICOM-compatible image archival workflows.

"With FDA clearance in hand, we can accelerate building the AI capabilities that will unlock the system's full diagnostic potential," said Delphine Le Roux, PhD, PMP, Senior Director, Market Access and Strategic Partnerships at RIVANNA. "The combination of an automated acquisition platform and AI-enabled fracture detection has the potential to democratize access to high-quality musculoskeletal imaging and reduce the burden on imaging resources in high-volume emergency settings."

The Accuro XV clearance follows the recent publication of a feasibility study demonstrating that non-physician operators can acquire diagnostic-quality extremity images following just one hour of hands-on training, with image quality comparable to that achieved by board-certified emergency physicians. The study, conducted at UVA Health and UT Southwestern Medical Center and published in the Journal of Emergency Medicine, enrolled 205 patients and found that more than 90% of scans in both operator groups were rated adequate for diagnostic interpretation.

About Accuro XV

Accuro XV is a portable, small-footprint point-of-care volumetric ultrasound imaging system for musculoskeletal imaging. The system features a conformable three-dimensional probe that automates large field-of-view B-mode image acquisitions without ionizing radiation. With AI-enabled decision-assist capabilities advancing toward FDA clearance, Accuro XV will deliver BoneEnhance, a machine learning software module that segments musculoskeletal anatomy to support 3D visualization of skeletal structures, and a CADe/x software module that uses machine learning to assist clinicians in detecting fractures from volumetric ultrasound imaging to support triage decisions, including referral for additional radiographic imaging.

Accuro XV is designed to provide a fracture-care layer at the point of triage — helping to streamline emergency department workflows, expedite evaluation of low-severity extremity injuries, and reduce reliance on X-ray referrals. The platform is designed to support just-in-time training to promote consistent use across clinical experience levels, advancing a shared mission to transform musculoskeletal injury care while supporting broader emergency preparedness objectives.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50121C00035.

About RIVANNA

RIVANNA® is a medical technology company developing clinical decision-support solutions powered by proprietary clinical datasets, AI models, and purpose-built imaging hardware. The company's platform automates complex anatomical analysis at the point of care, enabling faster, more confident clinical decisions while reducing variability and expanding access to advanced capabilities. The first applications target significant market opportunities in regional anesthesia and fracture care. Backed by 100+ patents, both products are on FDA 510(k) pathways and validated across multiple academic medical centers. RIVANNA is headquartered in Charlottesville, Virginia, and operates an FDA-registered, ISO 13485:2016-certified manufacturing facility.

SOURCE RIVANNA